MarketCap
Facebook
X
TelegramQuarterly report 2023-Q2
added 08-07-2023
Sigilon Therapeutics Revenue 2011-2026 | SGTX
Company revenue is the total amount of money received from the sale of goods or services over a certain period of time. It is one of the key indicators of a company's financial condition and success.
Traditionally defined as follows:Revenue = Price * Quantity of productsRevenue is one of the components of a company’s income. In international practice, revenue is understood as the inflow or other increase in a company's assets or the settlement of its obligations that occurs as a result of the company’s core or main activity.[1]
This is an important indicator for assessing the financial condition and efficiency of a company. It makes it possible to determine how successfully a company sells its products or services on the market. In addition, revenue can be used to calculate other financial indicators such as profit, profitability, and market share.
Various factors can influence this indicator, including demand for goods or services, market competition, economic conditions, and the company's marketing efforts. Therefore, its analysis and monitoring are important tasks for the successful development of a business.
Annual Revenue Sigilon Therapeutics
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 12.9 M | 9.6 M | 13.4 M | 14.2 M | 4.64 M | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 14.2 M | 4.64 M | 10.9 M |
Quarterly Revenue Sigilon Therapeutics
| 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 5.9 M | 4.86 M | - | 4.25 M | 2.88 M | 3.16 M | - | 1.95 M | 2.7 M | 2.96 M | - | 4.2 M | 1.95 M | 3.47 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 5.9 M | 1.95 M | 3.48 M |
References
- Adhikari, B. (2010). Impact of Revenue Planning In Nepal Investment Bank Limited (Doctoral dissertation, Faculty of Management).
Revenue of other stocks in the Biotechnology industry
| Issuer | Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
238 M | - | 2.43 % | $ 254 M |  Germany |
 |
Acasti Pharma
ACST
|
100 M | - | 4.01 % | $ 150 M |  Canada |
 |
AC Immune SA
ACIU
|
27.3 M | $ 2.72 | 7.51 % | $ 229 M |  Schweiz |
 |
Adverum Biotechnologies
ADVM
|
1 M | - | - | $ 86.2 M |  USA |
 |
AgeX Therapeutics
AGE
|
142 K | - | -10.17 % | $ 12.2 K | USA |
 |
Aeglea BioTherapeutics
AGLE
|
886 K | - | - | $ 1.01 B | USA |
 |
AIkido Pharma
AIKI
|
18.1 M | - | 1.93 % | $ 17.4 M | USA |
 |
Aptorum Group Limited
APM
|
912 K | $ 0.81 | 1.28 % | $ 4.42 M |  China |
 |
I-Mab
IMAB
|
88 M | - | - | $ 866 M | China |
 |
argenx SE
ARGX
|
36.4 M | $ 840.28 | 1.7 % | $ 25 B |  Niderland |
 |
Ascendis Pharma A/S
ASND
|
720 M | $ 234.99 | 0.02 % | $ 5 B |  Danmark |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
6.07 B | - | - | $ 40.3 B | USA |
 |
Albireo Pharma
ALBO
|
40.6 M | - | -0.23 % | $ 916 M | USA |
 |
Alterity Therapeutics Limited
ATHE
|
109 K | $ 3.33 | 0.79 % | $ 8.01 B |  Australia |
 |
Atea Pharmaceuticals
AVIR
|
351 M | $ 4.65 | 1.31 % | $ 392 M | USA |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
12.1 K | - | -1.52 % | $ 24.7 M | USA |
 |
AlloVir
ALVR
|
165 K | - | 4.14 % | $ 49.1 M | USA |
 |
Midatech Pharma plc
MTP
|
381 K | - | -18.52 % | $ 27.3 M |  Britain |
 |
Ampio Pharmaceuticals
AMPE
|
1.16 M | - | -11.43 % | $ 502 K | USA |
 |
BioMarin Pharmaceutical
BMRN
|
2.85 B | $ 62.62 | -0.48 % | $ 11.9 B | USA |
 |
Acorda Therapeutics
ACOR
|
118 M | - | -24.86 % | $ 820 K | USA |
 |
Acer Therapeutics
ACER
|
1.26 M | - | 2.71 % | $ 14 M | USA |
 |
Aravive
ARAV
|
9.14 M | - | -13.39 % | $ 1.45 M | USA |
 |
Capricor Therapeutics
CAPR
|
25.2 M | $ 27.91 | 0.14 % | $ 747 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
1.08 B | - | - | - |  Russia |
 |
CASI Pharmaceuticals
CASI
|
30.2 M | $ 0.8 | 5.68 % | $ 109 M | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
325 K | - | - | $ 26.5 M | USA |
 |
Catalyst Biosciences
CBIO
|
113 M | $ 12.65 | 10.29 % | $ 833 M | USA |
 |
Axsome Therapeutics
AXSM
|
638 M | $ 169.95 | -2.75 % | $ 8.45 B | USA |
 |
Ayala Pharmaceuticals
AYLA
|
692 K | - | - | $ 7.46 M |  Israel |
 |
Alpine Immune Sciences
ALPN
|
30.1 M | - | - | $ 2.17 B | USA |
 |
BioDelivery Sciences International
BDSI
|
167 M | - | -4.8 % | $ 255 M | USA |
 |
Aeterna Zentaris
AEZS
|
9.59 M | - | 5.93 % | $ 314 M | Canada |
 |
BeiGene, Ltd.
BGNE
|
3.81 B | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Biogen
BIIB
|
9.89 B | $ 195.13 | -0.62 % | $ 28.6 B | USA |
 |
Cellectis S.A.
CLLS
|
41.5 M | $ 3.98 | 0.51 % | $ 116 M |  France |
 |
Bellicum Pharmaceuticals
BLCM
|
1.5 M | - | -9.72 % | $ 5.89 M | USA |
 |
Baudax Bio
BXRX
|
1.27 M | - | 0.59 % | $ 63 K | USA |
 |
Aptinyx
APTX
|
1 M | - | -39.0 % | $ 4.57 M | USA |